PD15 External Validation Of The Budget Impact Analysis Of The Drug Fingolimod In The Treatment Of Multiple Sclerosis
Cesar Ricardo S Campello, Márcia Gisele Costa, Marcia Pinto · 2025
Read PD15 External Validation Of The Budget Impact Analysis Of The Drug Fingolimod In The Treatment Of Multiple Sclerosis by Cesar Ricardo S Campello, Márcia Gisele Costa, Marcia Pinto (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768748.txt.
Description
Cesar Ricardo Campello, Marcia Gisele Costa, and Marcia Pinto check a drug budget forecast against reality in a 2025 health costs study. Fingolimod treats relapsing-remitting multiple sclerosis, and Brazil's public health system adopted it after a budget impact analysis projected the cost. Years later, the authors validate that analysis from outside, comparing the assumptions in the incorporation report with the real parameters that emerged after adoption.
Outside checks of budget forecasts are rare and valuable: they show whether the models behind coverage decisions deserve trust. The fingolimod case offers Brazil's system a rare real-world answer.
Catalog record
| CREATOR | Cesar Ricardo S Campello, Márcia Gisele Costa, Marcia Pinto |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |